JP2018535952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535952A5 JP2018535952A5 JP2018519423A JP2018519423A JP2018535952A5 JP 2018535952 A5 JP2018535952 A5 JP 2018535952A5 JP 2018519423 A JP2018519423 A JP 2018519423A JP 2018519423 A JP2018519423 A JP 2018519423A JP 2018535952 A5 JP2018535952 A5 JP 2018535952A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- lipid
- popc
- distearoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 29
- 150000002632 lipids Chemical class 0.000 claims 10
- 239000002245 particle Substances 0.000 claims 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 239000000084 colloidal system Substances 0.000 claims 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims 4
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- -1 polyhydroxyethylene stearate Polymers 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- ZGCHLAJIRWDGFE-UHFFFAOYSA-N 1-aminopropane-1,1-diol Chemical compound CCC(N)(O)O ZGCHLAJIRWDGFE-UHFFFAOYSA-N 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 229960000182 blood factors Drugs 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518172.0 | 2015-10-14 | ||
| GBGB1518172.0A GB201518172D0 (en) | 2015-10-14 | 2015-10-14 | Colloidal particles for use in medicine |
| PCT/EP2016/074759 WO2017064276A1 (en) | 2015-10-14 | 2016-10-14 | Colloidal particles for use in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535952A JP2018535952A (ja) | 2018-12-06 |
| JP2018535952A5 true JP2018535952A5 (https=) | 2019-12-26 |
| JP7160678B2 JP7160678B2 (ja) | 2022-10-25 |
Family
ID=55131025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519423A Active JP7160678B2 (ja) | 2015-10-14 | 2016-10-14 | 医薬用コロイド粒子 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190192664A1 (https=) |
| EP (1) | EP3362039A1 (https=) |
| JP (1) | JP7160678B2 (https=) |
| KR (1) | KR20180067616A (https=) |
| CN (1) | CN108472246A (https=) |
| AU (1) | AU2016336929B2 (https=) |
| BR (1) | BR112018007399A2 (https=) |
| CA (1) | CA3036111C (https=) |
| EA (1) | EA201890703A1 (https=) |
| GB (1) | GB201518172D0 (https=) |
| HK (1) | HK1256814A1 (https=) |
| IL (1) | IL258567B2 (https=) |
| MX (1) | MX391574B (https=) |
| SG (2) | SG10202010711UA (https=) |
| WO (1) | WO2017064276A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021092580A1 (en) * | 2019-11-07 | 2021-05-14 | The Board Of Trustees Of The University Of Illinois | Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation |
| GB202111757D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111758D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111759D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0815852A1 (en) | 1993-08-06 | 1998-01-07 | Opperbas Holding B.V. | A method for high loading of vesicles with biopolymeric substances |
| US6593294B1 (en) | 1998-04-27 | 2003-07-15 | Opperbas Holding B.V. | Pharmaceutical composition comprising Factor VIII and neutral liposomes |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| DK1198490T3 (da) | 1999-07-14 | 2006-06-19 | Alza Corp | Neutral lipopolymer og liposomsammensætninger indeholdende samme |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| CN1774281B (zh) * | 2003-04-15 | 2010-10-13 | 奥珀百思控股公司 | 包含蛋白质和/或多肽以及胶体颗粒的药物组合物 |
| CA2613705A1 (en) * | 2005-06-29 | 2007-01-04 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic pr0tein-lip1d complexes |
| CN105434353A (zh) | 2009-06-03 | 2016-03-30 | 斯昆申技术控股有限责任公司 | 用于治疗深部组织疼痛的制剂 |
| GB2486371A (en) | 2009-08-21 | 2012-06-13 | Targeted Delivery Technologies Ltd | Vesicular formulations |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| MY190257A (en) | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| CN107879960B (zh) * | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
-
2015
- 2015-10-14 GB GBGB1518172.0A patent/GB201518172D0/en not_active Ceased
-
2016
- 2016-10-14 EA EA201890703A patent/EA201890703A1/ru unknown
- 2016-10-14 KR KR1020187013254A patent/KR20180067616A/ko not_active Ceased
- 2016-10-14 JP JP2018519423A patent/JP7160678B2/ja active Active
- 2016-10-14 AU AU2016336929A patent/AU2016336929B2/en not_active Ceased
- 2016-10-14 BR BR112018007399A patent/BR112018007399A2/pt not_active Application Discontinuation
- 2016-10-14 IL IL258567A patent/IL258567B2/en unknown
- 2016-10-14 CN CN201680073237.XA patent/CN108472246A/zh active Pending
- 2016-10-14 MX MX2018004445A patent/MX391574B/es unknown
- 2016-10-14 CA CA3036111A patent/CA3036111C/en active Active
- 2016-10-14 US US15/768,381 patent/US20190192664A1/en not_active Abandoned
- 2016-10-14 HK HK18115899.0A patent/HK1256814A1/zh unknown
- 2016-10-14 EP EP16781807.9A patent/EP3362039A1/en active Pending
- 2016-10-14 SG SG10202010711UA patent/SG10202010711UA/en unknown
- 2016-10-14 SG SG11201802956RA patent/SG11201802956RA/en unknown
- 2016-10-14 WO PCT/EP2016/074759 patent/WO2017064276A1/en not_active Ceased
-
2020
- 2020-05-26 US US16/883,338 patent/US20210093721A1/en not_active Abandoned
-
2024
- 2024-06-24 US US18/752,365 patent/US20250170244A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing | |
| JP2015527391A (ja) | ヒアルロン酸をベースとする薬物送達システム | |
| Yu et al. | Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly (lactic-co-glycolic acid) | |
| Ding et al. | Nanospheres-incorporated implantable hydrogel as a trans-tissue drug delivery system | |
| TWI556838B (zh) | 治療關節炎之方法 | |
| JP5702734B2 (ja) | 局所投与に好適なイミダゾキノリン（アミン）及びその誘導体を含む医薬組成物 | |
| JP2020073617A (ja) | 免疫療法のための調節粒子 | |
| Stillman et al. | Aluminum-based metal–organic framework nanoparticles as pulmonary vaccine adjuvants | |
| Wang et al. | Bisphosphonate‐decorated lipid nanoparticles designed as drug carriers for bone diseases | |
| Salzano et al. | Self-assembly nanoparticles for the delivery of bisphosphonates into tumors | |
| JP2018535952A5 (https=) | ||
| Zhao et al. | Remodeling the hepatic fibrotic microenvironment with emerging nanotherapeutics: a comprehensive review | |
| CN101829046B (zh) | 一种两亲性嵌段聚合物胶束纳米载药系统及制备方法 | |
| CN106237340B (zh) | 透明质酸纳米颗粒在制备治疗淋巴系统肿瘤的药物的用途 | |
| JP2008517878A5 (https=) | ||
| JP2017507968A (ja) | 粘膜送達用のリポソーム組成物 | |
| Vijayan et al. | Dual growth factor entrapped nanoparticle enriched alginate wafer-based delivery system for suppurating wounds | |
| Garland et al. | Microparticle depots for controlled and sustained release of endosomolytic nanoparticles | |
| Tao et al. | Liposomal stabilization using a sugar-based, PEGylated amphiphilic macromolecule | |
| Benedini et al. | Nanodevices for facing new challenges of medical treatments: Stimuli-responsive drug delivery systems | |
| Gao et al. | A rod bacterium-like magnetic polymer micelle for strongly enhancing selective accumulation and internalization of nanocarriers | |
| HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi | |
| US11191853B2 (en) | Post-surgical imaging marker | |
| JP2010503689A5 (https=) | ||
| CA3148042A1 (en) | Pharmaceutical composition for otic administration |